{"id":341102,"date":"2026-11-05T22:43:18","date_gmt":"2026-11-05T17:13:18","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q2-results-fy27-pat-264-crore\/"},"modified":"2026-11-05T22:43:18","modified_gmt":"2026-11-05T17:13:18","slug":"glenmark-pharmaceuticals-q2-results-fy27-pat-264-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/glenmark-pharmaceuticals-q2-results-fy27-pat-264-crore\/","title":{"rendered":"Glenmark Pharmaceuticals Q2 Results FY27: Revenue Falls 31.97% to Rs 4,249.87 Cr, PAT Rs 263.83 Cr"},"content":{"rendered":"
\n

Quick Answer<\/strong><\/p>\n

Glenmark Pharmaceuticals Q2 Results FY27 were declared on 5 November 2026. The quarterly results show consolidated revenue of Rs 4,249.87 Cr, down 31.97% YoY, and net profit of Rs 263.83 Cr, down 56.78% YoY. Operating Profit came in at Rs 773.57 Cr, so the YoY growth reading is negative across all three headline lines.<\/p>\n<\/div>\n

Glenmark Pharmaceuticals Ltd<\/a> (GLENMARK) Q2 Results FY27 announced on 5 November 2026, covering the company’s financial performance for the July to September quarter. Consolidated revenue was Rs 4,249.87 Cr against Rs 6,247.50 Cr a year earlier. In Glenmark Pharmaceuticals Q2 Results FY27, PAT stands at Rs 263.83 Cr and the results date for this NSE and BSE disclosure is 5 November 2026.<\/p>\n

This Glenmark Pharmaceuticals Q2 Results results analysis covers the financial highlights, the business drivers supplied for the company, the outlook for FY27 and the risks investors can track. Every figure below is a consolidated results figure for the quarter, so the table of numbers is the right place to start.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n